LOS ANGELES, May 12, 2020 /PRNewswire-PRWeb/ — Modere (the “Company”), a healthy, safe and clean-lifestyle brand of dietary supplements, household, and personal care products with a presence worldwide, today announced the definitive results of two third-party clinical trials conducted on the company’s new collagen and hyaluronic acid-based face serum, CellProof ® Serum.
Measured at two and/or four weeks, the skin’s appearance measurably improved in all or nearly all test subjects across five test categories. At both two and four weeks, 100% of test subjects experienced increased skin hydration, and at two weeks 80% of users experienced improved skin tone. Over four weeks, skin texture and density improved in 85% of users, while exfoliation increased in 92% of test subjects. An additional clinical trial further validated CellProof® Serum’s effect on skin health – showing significant reduction in the appearance of wrinkles.
“While we have been highly confident in the exceptional quality of our state-of-the-art face serum, CellProof, since its release last June, it is gratifying to receive such categorical validation of our product’s efficacy,” stated Asma Ishaq, CEO of Modere.
Modere CellProof® Serum’s exclusive formula combines patented, cosmetic grade BioCell Collagen® CG with a potent botanical complex and Vitamin C to hydrate, firm, and visibly lift and illuminate the skin within minutes. The topical serum’s age-defying benefits are compounded when used in tandem with the company’s award-winning nutraceutical, Liquid BioCell®.
